We are here to help. Your condition may be rare, but you are not alone.

We work with patient groups, the Australian Red Cross Blood Service, researchers, physicians and professional bodies, nurses, pharmacists, government and home healthcare companies to promote quality care, improve patient access to care, expand educational outreach efforts, and contribute to public healthcare policy. We know and understand our patients better than just about anyone and we are proud to offer a range of quality products. We continue to introduce new innovations that address unmet medical needs or enhance current treatments. We are first and foremost focused on fulfilling our patients' needs.

CSL Behring collaborates with rare disease patient organizations at the international, regional, national and local levels to promote quality medical care and services and to improve and expand educational and outreach efforts. Through these partnerships, we strive to raise public awareness and to enhance appropriate public policies for rare diseases.

In Europe, CSL Behring partners with EURORDIS, the European Organization for Rare Diseases. EURORDIS is a patient-driven alliance of representatives from patient organizations and others active in the field of rare diseases. EURORDIS’ mission is to build a strong pan-European community of patient organizations and people living with rare diseases, to be their voice at the European level, and -- directly or indirectly -- to fight against the impact of rare diseases on their lives.

In the United States, CSL Behring partners with the National Organization for Rare Disorders (NORD), an umbrella organization of patient advocacy organizations dedicated to individuals with rare diseases. NORD, along with its more than 260 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services. CSL Behring serves on the NORD Corporate Council, a group of innovative companies who have and are developing therapies for the treatment of rare disorders, which helps to find commonality and discuss legislative activity to ensure the continued development of rare disease therapies.

CSL Behring has been recognized by NORD over the years for manufacturing cutting-edge therapies, winning its Industry Innovation Award on multiple occasions, most recently in 2017.